Gαi1 Promoted Proliferation, Migration and Invasion via Activating the Akt-mTOR/Erk-MAPK Signaling Pathway in Renal Cell Carcinoma. 2021

Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, People's Republic of China.

BACKGROUND Renal cell carcinoma (RCC) accounts for about 2-3% of all adult malignancies. G protein alpha inhibitory subunit 1 (Gαi1) plays a key role in mediating PI3K-Akt signaling upon activation of receptor tyrosine kinases (RTKs). However, little is known about its expression, regulation and biological function in RCC. METHODS Gαi1 expression in RCC tissues and cells was detected by quantitative real-time PCR (qRT-PCR), Western blot and immunohistochemistry (IHC). The effect of Gαi1 silence on cell proliferation and apoptosis of 786-O and ACHN cells was detected by CCK-8 assay and flow cytometry. Wound-healing assay and Transwell assays were used to detect the cell invasion in RCC cells. The expression of CDK4, cyclin D1, MMP-2, MMP-9, Bax, Bcl-2, p/t-Akt, p/t-S6 and p/t-Erk was detected by Western blot and qRT-PCR. Furthermore, a nude mouse subcutaneous xenograft model was used to further evaluate the potential effects of Gail in vivo. RESULTS In the present study, our data showed that Gαi1 expression was dramatically increased in RCC tissues compared with normal renal tissues. In addition, knocking down the expression of Gαi1 subsequently inhibited proliferation, migration and invasion of RCC cells in vivo and vitro. Furthermore, the expression of CDK4, cyclin D1, MMP-2 and MMP-9 was significantly reduced upon Gαi1 inhibition. Gαi1 positively regulates the activation of the mTOR and Erk pathways. CONCLUSIONS In conclusion, this study reveals Gαi1 promoted proliferation via activating the Akt-mTOR and Erk-MAPK signaling pathways in RCC, and Gαi1 may be a therapeutic and prognostic target for RCC.

UI MeSH Term Description Entries

Related Publications

Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2020, BioMed research international,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2019, International journal of biological sciences,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
July 2019, Molecular and cellular biochemistry,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
December 2021, Molecular medicine reports,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2019, Cancer management and research,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
May 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2021, Cancer biomarkers : section A of Disease markers,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2020, Oncology letters,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
September 2023, Cancer cell international,
Zhan Chen, and Yong Zhang, and Xiang Wu, and Ji Zhang, and Wei Xu, and Cheng Shen, and Bing Zheng
January 2022, Frontiers in genetics,
Copied contents to your clipboard!